International Journal of Endocrinology / 2018 / Article / Tab 2 / Research Article
Is a Combination of a GnRH Agonist and Recombinant Growth Hormone an Effective Treatment to Increase the Final Adult Height of Girls with Precocious or Early Puberty? Table 2 Characteristics of included studies of girls with early puberty.
Authors (year) Comparison Treatment Duration of therapy Subjects (n ) Before treatment After treatment CA (years) BA (years) Height (cm) HSDS PAH (cm) FAH (cm) FAHSDS Job et al. 1994 [11 ] GH GH 0.1 IU/kg/day, sc. 3 yr. 7 France ISS 12.2 ± 1.5 10.4 ± 0.8 131.4 ± 6.4 −2.8 ± 0.5 148.7 ± 8.3 152.8 ± 6.4 −1.1 ± 1.5 GnRHa + GH GH + trip 3.75 mg/28 days, i.m. 6 France ISS 12.3 ± 0.7 10.5 ± 0.7 133.3 ± 6.8 −2.8 ± 0.5 150.8 ± 9.2 154.6 ± 8.4 −1.3 ± 1.2 Saggese et al. 1995 [18 ] Control No treatment 2.0 ± 0.5 yr. 7 Italy short children 11.3 ± 0.6 11.0 ± 0.8 NA −1.5 ± 0.7 149.0 ± 4.5 152.0 ± 3.4 −1.7 ± 0.5 GnRHa + GH Trip 60 μ g/kg/28 days + GH 0.65 IU/kg/wk, sc. 7 Italy short children 11.5 ± 0.9 11.5 ± 0.8 −1.8 ± 0.6 146.8 ± 4.4 156.1 ± 2.1 −0.9 ± 0.3 Lanes and Gunczler 1998 [12 ] Control No treatment 2.5 yr. 10 USA ISS 11.4 ± 1.0 11.0 ± 0.8 128.9 ± 7.8 −2.3 ± 0.4 151.8 ± 10.1 150.3 ± 9.8 −2.9 ± 0.8 GnRHa + GH Leup 0.3 mg/kg/28 days, i.m. + GH 0.1 U/kg/day, sc. 10 USA ISS 11.8 ± 1.3 11.2 ± 0.9 128.9 ± 7.5 −2.4 ± 0.4 150.7 ± 9.8 151.7 ± 2.4 −2.7 ± 0.6 van Gool et al. 2007 [13 ] Control No treatment 3 yr. 15 Netherlands SGA/ISS 11.8 ± 0.7 NA 136.1 ± 4.5 −2.5 ± 0.5 160.0 ± 10.1 159.5 ± 5.7 −2.3 ± 0.6 GnRHa + GH GH 0.14 IU/kg/day, sc. + trip 3.75 mg/28 days, i.m. 17 Netherlands SGA/ISS 11.6 ± 0.7 135.4 ± 4.5 −2.4 ± 0.5 157.4 ± 8.3 161.8 ± 6.3 −2.0 ± 1.0 van der Steen et al. 2016 [27 ] GH GH 1–2 mg/m2 /day, sc. 5.9 yr. 43 Dutch SGA 7.6 ± 3.2 NA NA −2.3 ± 0.7 NA NA −1.7 ± 0.8 GnRHa + GH Leup 3.75 mg/kg/28 days, sc. + GH 64 Dutch SGA 7.3 ± 3.1 −2.8 ± 0.6 −1.8 ± 0.9
Trip is triptorelin. i.m. is intramuscularly. Leup is leuprolide. sc. is subcutaneous.